DIG
INMB icon

Dauntless Investment Group’s INmune Bio INMB Stock Holding History

Dauntless Investment Group’s Portfolio INMB Stock Details INMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-93,400
Closed -$117K – 86
2025
Q2 		$117K Buy
93,400
+25,400
+37% +$186K 0.2% 51
2025
Q1 		$531K Buy
+68,000
New +$540K 0.62% 31

Other funds holding INMB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Dauntless Investment Group's INMB Position: Q1 2026 in Review

Dauntless Investment Group reduced its INmune Bio (INMB) stake by 40% in Q1 2026, selling an estimated $173K and leaving 183,476 shares worth $207K. The position accounts for 0.14% of the portfolio, ranked #45.

Dauntless Investment Group first reported a position in INMB in Q4 2024 and has held it in 5 quarters since. The position peaked at $1.02M in Q1 2025. 82 funds tracked by Wall St. Rank hold INMB as of Q1 2026.

  • Dauntless Investment Group held 183,476 shares of INmune Bio worth $207K as of Q1 2026.
  • Dauntless Investment Group sold 121,446 INmune Bio shares in Q1 2026, an estimated $173K.
  • INmune Bio made up 0.14% of Dauntless Investment Group's portfolio in Q1 2026, its #45 holding.
  • Dauntless Investment Group first reported a position in INmune Bio in Q4 2024 and has held it in 5 quarters since.
  • Dauntless Investment Group's INmune Bio position peaked at $1.02M in Q1 2025.
  • 82 funds tracked by Wall St. Rank held INmune Bio as of Q1 2026.

Based on Dauntless Investment Group's 13F filing for Q1 2026, filed 14 May 2026.